Search filters
Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

28/04/2022

From May 1st 2022 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease (CKD) is fully reimbursed...

Extension to TerugBetaalRegeling Elvanse®

Extension to TerugBetaalRegeling Elvanse®

01/04/2022

The health insurer does not fully reimburse Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The manufacturer of this...

Reimbursement Scheme Ontozry® (12.5mg/50mg, 50 mg, 100 mg, 150mg)

Reimbursement Scheme Ontozry® (12.5mg/50mg, 50 mg, 100 mg, 150mg)

24/03/2022

The health insurer does not fully reimburse ONTOZRY® (12.5mg/50mg, 50 mg, 100 mg, 150mg). The producer of this medicine has...

Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

11/03/2022

The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction...

Extension to TerugBetaalRegeling Acecort®

Extension to TerugBetaalRegeling Acecort®

09/03/2022

Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The...

You are currently offline. Some pages or content may fail to load.